A recent Phase 2b clinical trial, STREAM-AD, showed that amlitelimab, a non-T cell depleting monoclonal antibody that blocks OX40L on antigen-presenting cells, exhibited sustained treatment effects on patients with atopic dermatitis [87]. The gene discussed is TNFSF4; the disease is atopic eczema.